** Shares of gene therapy maker bluebird bio BLUE.O fall 38.6% to $4.32 premarket
** Co says it would be taken private by Carlyle CG.O and SK Capital Partners
** BLUE stockholders will receive $3/shr in cash, implying an equity value of around $29.2 mln
** The offer is at an over 57% discount from the stock's last close of $7.04
** Investment firms have also offered additional $6.84/shr, contingent upon achieving certain sales milestones, which represents a payment of about $66.5 mln
** BLUE fell 69.8% in 2024
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.